Combining treatments that target gene packaging and RNA changes in prostate cancer
Combinational targeting histone and RNA modifications in prostate cancer
A combined approach targeting a gene-regulating protein (EZH2) and chemical marks on RNA (m6A) to help men with advanced or treatment-resistant prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11318909 on NIH RePORTER |
What this research studies
This work looks at drugs and approaches that change how DNA is packaged (via EZH2) together with ways to alter chemical marks on RNA (m6A) to try to stop prostate cancer growth. Researchers will use lab-grown prostate cancer cells, disease models that mimic resistant or metastatic tumors, and analyze patient tumor samples to link findings to real cancers. The team will test combinations that might make existing therapies work better against tumors that have become resistant. Successful lab findings could guide future clinical testing at medical centers.
Who could benefit from this research
Good fit: Men with advanced, recurrent, or treatment-resistant prostate cancer, particularly those whose tumors show high EZH2 activity, would be the most relevant candidates.
Not a fit: People with early-stage, low-risk prostate cancer or cancers not driven by EZH2-related RNA changes are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, the project could identify combination therapies that overcome resistance and improve outcomes for men with advanced prostate cancer.
How similar studies have performed: Targeting EZH2 and RNA modifications is an emerging strategy with encouraging preclinical data but limited clinical proof to date.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Cao, Qi — Northwestern University
- Study coordinator: Cao, Qi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.